Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
10 participants
INTERVENTIONAL
2025-09-10
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary hypothesis: A flexible acupuncture and Chinese herbal medicine protocol will be feasible, acceptable, and useful for the treatment of long COVID.
Secondary hypothesis: Long COVID patients receiving acupuncture treatment or acupuncture treatment and Chinese herbal supplements over an 8-week period will see improvements in their symptoms, function, and quality of life measurements.
Specific Aims of This Research (Purpose of the study):
To study the feasibility, acceptability and utility of an acupuncture and Chinese herbal supplement treatment protocol for patients with long COVID and preliminarily assess the effects of treatment.
Currently Available Research on This Subject:
Studies indicate that acupuncture can effectively treat symptoms that are similar to those often seen in long COVID patients. Additionally, recent studies and clinical evidence suggest that there is substantial potential for acupuncture in the treatment of long COVID. Acupuncture may be beneficial because it can address many symptoms simultaneously with a single intervention, whereas symptom clusters can be difficult to manage with pharmaceuticals due to the need for multiple pharmaceutical agents.
Summary of the research protocol/methodology:
Five patients will receive acupuncture treatment, and five patients will receive acupuncture and Chinese herbal medicine. Each participant will receive 16 acupuncture treatments over the course of eight weeks (i.e., twice per week). Each treatment session will last for 30 minutes. Follow-up will occur at 12 weeks (i.e., four weeks after the final treatment session).
Significance of this research to the health and welfare of general public:
There is currently not a single, specific treatment for long COVID. If acupuncture treatment alone and/or acupuncture and Chinese herbal medicine combined are feasible, acceptable, and efficacious in the improvement of long COVID symptoms, it will offer patients additional treatment options, which may help some patients to avoid pharmaceutical treatment side effects or polypharmacy challenges.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pragmatic experimental arm
Single-arm study looking at feasibility and acceptability of acupuncture treatment for 5 patients and acupuncture and Chinese herbal medicine for 5 patients
Acupuncture
The investigators have developed a list of core acupoints, which will be used by all clinicians for each specific TCM diagnosis pattern identified in each patient. Similarly, a list of common herbal formulas, that we will keep in stock based on the specific diagnosis patterns, has been developed. Clinicians will have the option of using additional acupoints as necessary and will be asked to record and explain any variations from the core protocol.
1. Residual Heat: LI-11, KI-6;Bai He Gu Jin Tang
2. Residual Phlegm: ST-40, Sp-9;Ban Xia Bai Zhu Tian Ma Tang,Er Chen Tang
3. Deficiency of Spleen: SP-3, ST-36;Gui Pi Tang,Xiang Sha Liu Jun Zi Tang
4. Lung Qi Deficiency with Dampness: LU-9, LU-7;Zhi Sou San,Er Chen Tang
5. Blood Stagnation: SP-10, SP-6;Xue Fu Zhu Yu Tang,Tao Hong Si Wu Tang
6. Deficiency of Lung: LU-9, LU-7; Bu Fei Tang
7. Liver Qi Stagnation: LV-3, PC-6;Xiao Yao San, Chai Hu Shu Gan Tang
8. Yin Deficiency: KI-6, SP-6;Liu Wei Di Huang Wan
9. Deficiency of Kidney: KI-3, KI-6;
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acupuncture
The investigators have developed a list of core acupoints, which will be used by all clinicians for each specific TCM diagnosis pattern identified in each patient. Similarly, a list of common herbal formulas, that we will keep in stock based on the specific diagnosis patterns, has been developed. Clinicians will have the option of using additional acupoints as necessary and will be asked to record and explain any variations from the core protocol.
1. Residual Heat: LI-11, KI-6;Bai He Gu Jin Tang
2. Residual Phlegm: ST-40, Sp-9;Ban Xia Bai Zhu Tian Ma Tang,Er Chen Tang
3. Deficiency of Spleen: SP-3, ST-36;Gui Pi Tang,Xiang Sha Liu Jun Zi Tang
4. Lung Qi Deficiency with Dampness: LU-9, LU-7;Zhi Sou San,Er Chen Tang
5. Blood Stagnation: SP-10, SP-6;Xue Fu Zhu Yu Tang,Tao Hong Si Wu Tang
6. Deficiency of Lung: LU-9, LU-7; Bu Fei Tang
7. Liver Qi Stagnation: LV-3, PC-6;Xiao Yao San, Chai Hu Shu Gan Tang
8. Yin Deficiency: KI-6, SP-6;Liu Wei Di Huang Wan
9. Deficiency of Kidney: KI-3, KI-6;
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* We will include adults of any age in our study. Adults of all ages can experience long COVID symptoms, although it is more common in older adults
• Confirmed and documented COVID-19 illness (confirmed by healthcare provider or test; acceptable documentation includes but is not limited to a doctor's note or a photo of test result)
* COVID-19 illness is a necessary precursor to the development of long COVID
• Experiencing at least one of the following common long COVID symptoms for at least 4 weeks after confirmed COVID-19 illness:
* Fatigue or post-exertional malaise,
* Dyspnea, cough,
* Brain fog, sleep disturbance, depression, anxiety,
* Arthralgia, myalgia, or
* Constipation, diarrhea, stomach pain
* Over 200 different long COVID symptoms have been identified. The proposed study is a small pragmatic pilot study which only plans to enroll 10 participants. It is necessary to limit inclusion to some of the most common symptoms to ensure that the findings are broadly relevant across the long COVID patient population.
* The symptoms were not present prior to the confirmed COVID-19 illness
o If the symptoms were present prior to the confirmed COVID-19 illness, then they are most likely attributable to a cause other than long COVID
* Willingness to comply with the treatment schedule
o It is important that all those who qualify for the study are willing to comply with the protocol that is being adopted. If the patient is not willing to attend acupuncture treatment sessions or comply with the supplement schedule, then they may not be enrolled in the study.
* Ability to read and understand English o Informed consent will be in the English language. Inability to read and understand English will interfere with provision of informed consent. Moreover, compliance is a potential issue with herbal supplementation. Recruiting patients who are able to read and understand English instructions for supplement intake will help to improve compliance with the protocol.
* Ability to provide informed consent o It is important that participants are aware that they are required to provide written informed consent before they are allowed to participate. Some individuals who are eligible might be unwilling to sign the informed consent form.
Exclusion Criteria
* Pulmonary fibrosis or on continuous oxygen treatment
* Certain preexisting conditions:
* Diagnosed with Alzheimer's or demonstrating onset of dementia
* Uncontrolled hypertension, diabetes, or autoimmune conditions
* Other comorbid conditions that might imitate long COVID symptoms
* Undergoing cancer treatments
* Use of acupuncture or Chinese medicine in the past three months
* Involved in health-related litigation or legal claims
* Missing either baseline visit and deemed unlikely to comply with the study protocol
* Pregnant or breastfeeding or trying to get pregnant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Southern California University of Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SCUHS
Whittier, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
S. Prasad Vinjamury, MD (Ayurveda) DACM, MPH
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VINJ011
Identifier Type: OTHER
Identifier Source: secondary_id
VINJ011
Identifier Type: -
Identifier Source: org_study_id